Ab-Interno Canaloplasty Standalone Versus Combined With Cataract Surgery – 36-Month Outcomes In +1000 Eyes
Published 2022
- 40th Congress of the ESCRS
Reference: FPM04.03
| Type: Free paper
| DOI:
10.82333/x9rz-vq28
Authors:
Mahmoud Khaimi* 1
, Kai Ding 2
1Dean McGee Eye Institute - Oklahoma Health Center,Oklahoma City,United States, 2Department of Biostatistics and Epidemiology,University of Oklahoma Health Sciences Center,Oklahoma City,United States
Purpose
To investigate the clinical outcomes of ab-interno canaloplasty (ABiC) with iTrack microcatheter (Nova Eye Medical) performed as a standalone procedure (ABiC) and in combination with phacoemulsification (ABiC+phaco) over a 36-month period.
Setting
Dean McGee Eye Institute/University of Oklahoma in Oklahoma City
Methods
Non-randomized, single center, retrospective case series of eyes undergoing either ABiC or ABiC+phaco. Adult patients with controlled and uncontrolled open-angle glaucoma and no prior glaucoma surgery were eligible for inclusion. Outcome measures include intraocular pressure (IOP) and number of glaucoma medications.
Results
1013 eyes (335 ABiC and 678 ABiC+phaco) were included. Mean baseline IOP was 21.7±7.1mmHg (ABiC) and 18.5±7.3mmHg (ABiC+phaco) and glaucoma medication number was 2.11±1.17 (ABiC) and 1.72±1.13 (ABiC+phaco). There was a statistically significant difference among the groups at baseline (p<0.001). At 36 months, mean IOP was reduced to 17.0±4.0 mmHg (n=10) and 14.4±3.3 mmHg (n=41) respectively, and mean number of medications was reduced to 1.42±0.90 (n=12) and 0.88±1.13 (n=42) respectively with was no significant statistical difference between groups (p=0.18; p=0.44). Ninety-nine eyes experienced adverse events such as postoperatively IOP spikes; 7 eyes had complications.
Conclusions
ABiC results in a sustained reduction in mean IOP and glaucoma medications when used as a standalone procedure or in combination with phacoemulsification.